Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Yu, Qiuyan ^a   Zhu, Zhenli ^a   Liu, Yan ^a   Zhang, Jun ^a   Li, Ke ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ARTICLE; BAYES THEOREM; BREAST CANCER; BREAST METASTASIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84930646139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127404     Document Type: Article

References (72)

1. Chu D, Lu J. Novel therapies in breast cancer: What is new from ASCO 2008. J Hematol Oncol 2008: 1:16. doi: 10.1186/1756-8722-1-16 PMID: 18828924
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: a cancer journal for clinicians. 2007; 57(1):43-66.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-182. PMID: 3798106
5. Vogel UF. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization. Diagnostic pathology. 2010; 5:50. doi: 10.1186/1746-1596-5-50 PMID: 20670419
6. Zahnow CA. ErbB receptors and their ligands in the breast. Expert reviews in molecular medicine. 2006; 8(23):1-21. PMID: 16984691
7. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. The Journal of clinical investigation. 2007; 117(8):2051-2058. PMID: 17671639
8. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HER-NATA study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(3):264-271.
9. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine. 2012; 366(2):109-119. doi: 10.1056/NEJMoa1113216 PMID: 22149875
10. Baselga J, Manikhas A, Cortes J, Llombart A, Roman L, Semiglazov VF, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014; 25(3):592-598.
11. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007; 110(5):965-972. PMID: 17614302
12. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 2013; 14(6):461-471. doi: 10.1016/S1470-2045(13)70130-X PMID: 23602601
13. McCormack PL. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 2013; 73(13):1491-1502. doi: 10.1007/s40265-013-0109-0 PMID: 23982598
14. Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(16):1947-1953.
15. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology. 2012; 13(2):135-144. doi: 10.1016/S1470-2045(11)70397-7 PMID: 22257523
16. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network: JNCCN. 2013; 11(7):753-761 PMID: 23847214
17. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(9):1157-1163.
18. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2012; 13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9 PMID: 22153890
19. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(14):1719-1725.
20. Miller KD, Dieras V, Harbeck N, Andre F, Mahtani RL, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(14):1437-1444.
21. Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24(10):2630-2635. doi: 10.1093/annonc/mdt274 PMID: 23868905
22. Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(36):4504-4511.
23. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 2013; 14(12):1183-1192. doi: 10.1016/S1470-2045(13)70411-X PMID: 24095300
24. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute. 2008; 100(24):1780-1791. doi: 10.1093/jnci/djn414 PMID: 19066278
25. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2011; 22(6):1308-1317. doi: 10.1093/annonc/mdq593 PMID: 21119031
26. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Jama. 2003; 289(19):2534-2544. PMID: 12759325
27. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557):201-207. PMID: 17240286
28. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. The Lancet Oncology. 2011; 12(1):65-82. doi: 10.1016/S1470-2045(10)70260-6 PMID: 21123111
29. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2007; 335(7626):925. PMID: 17932160
30. Owen A. Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. International journal of cardiology. 2010; 142(3):218-223. doi: 10.1016/j.ijcard.2009.11.045 PMID: 20061035
31. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (Clinical research ed). 2008; 337:a1331. doi: 10.1136/bmj.a1331 PMID: 18757996
32. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591):937-948. PMID: 17869634
33. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. The European respiratory journal. 2009; 34(3):634-640. doi: 10.1183/09031936.00167708 PMID: 19357145
34. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common anti-platelet regimens after transient ischaemic attack or stroke. European heart journal. 2008; 29(9):1086-1092. doi: 10.1093/eurheartj/ehn106 PMID: 18349026
35. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009; 373(9667):911-918. doi: 10.1016/S0140-6736(09)60319-6 PMID: 19286090
36. van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. Journal of clinical epidemiology. 2009; 62(12):1279-1283. doi: 10.1016/j.jclinepi.2008.04.012 PMID: 19716679
37. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (Clinical research ed). 2010; 341:c4675. doi: 10.1136/bmj.c4675 PMID: 20847017
38. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in medicine. 2004; 23(20):3105-3124. PMID: 15449338
39. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology. 2011; 64(2):163-171. doi: 10.1016/j.jclinepi.2010.03.016 PMID: 20688472
40. st ed. The Cochrane Collaboration Hoboken: Wiley-Backwell;2008.
41. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-758. doi: 10.1016/S0140-6736(09)60046-5 PMID: 19185342
42. Zhu Z, Zhang J, Liu Y, Chen M, Guo P, Li K. Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis. British journal of cancer. 2014; 110(10):2396-2404. doi: 10.1038/bjc.2014.197 PMID: 24736585
43. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials. 2007; 28(2):105-114. PMID: 16807131
44. st ed. United Kingdom: Wiley-Backwell; 2011.
45. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-560. PMID: 12958120
46. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics. 2006; 24(1):1-19. PMID: 16445299
47. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. Royal Statist Soc B. 2002; 64(4):583-639.
48. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. Journal of clinical epidemiology. 2010; 63(8):875-882. doi: 10.1016/j.jclinepi.2009.08.025 PMID: 20080027
49. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology. 1997; 50(6):683-691. PMID: 9250266
50. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Journal of clinical epidemiology. 2009; 62(8):857-864. doi: 10.1016/j.jclinepi.2008.10.001 PMID: 19157778
51. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. 2001; 344(11):783-792. PMID: 11248153
52. Eiermann W, International Herceptin Study G. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2001; 12 Suppl 1:S57-62.
53. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(19):4265-4274. PMID: 15911866
54. Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast cancer research and treatment. 2007; 101(3):355-365. PMID: 16850247
55. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(12):1999-2006.
56. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(33):5529-5537.
57. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast (Edinburgh, Scotland). 2012; 21(1):27-33. doi: 10.1016/j.breast.2011.07.006 PMID: 21862331
58. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine. 2012; 367(19):1783-1791. doi: 10.1056/NEJMoa1209124 PMID: 23020162
59. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. The oncologist. 2010; 15(9):924-934. doi: 10.1634/theoncologist.2009-0181 PMID: 20736298
60. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine. 2006; 355(26):2733-2743. PMID: 17192538
61. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. The oncologist. 2010; 15(2):122-129. doi: 10.1634/theoncologist.2009-0240 PMID: 20156908
62. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(33):5538-5546.
63. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(34):5544-5552. doi: 10.1200/JCO.2008.16.2578 PMID: 18955454
64. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine. 2012; 366(2):109-119. doi: 10.1056/NEJMoa1113216 PMID: 22149875
65. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(34):4491-4497.
66. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine. 2011; 365(14):1273-1283. doi: 10.1056/NEJMoa0910383 PMID: 21991949
67. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England journal of medicine. 2006; 354(8):809-920. PMID: 16495393
68. Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast cancer research and treatment. 2012; 135(2):347-354. doi: 10.1007/s10549-012-2157-7 PMID: 22782294
69. Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer treatment reviews. 2011; 37(4):312-320. doi: 10.1016/j.ctrv.2010.09.001 PMID: 20952131
70. Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther. 2010; 12(3):350-360. PMID: 20521224
71. Botrel TE, Paladini L, Clark OA. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis. Core evidence. 2013; 8:69-78. doi: 10.2147/CE.S50474 PMID: 24115917
72. Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. Journal of clinical epidemiology. 2001; 54(3):245-252. PMID: 11223322